Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Yes, good to hear from the prezzo that this new deal does not in any way interfere with the China JV which is a standalone deal. Phil said today the relationship with Weichai and Bosch remains very strong.... Put simply, he said a 3 way deal takes longer to finalise than a 2 way deal.
If 1/2 the £43mill Delta money is recognised this year and revenue is also achieved this yr via the China deal, then that would be some turnaround.
Maybe not a blockbuster rns but i see this as a good start for the Nanogenics work. Anyone who took the time to read the inital Nanogenics rns and the 2nd October presentation would not have realistically expected much more at this stage.
Dcraig i would not pay much attention to that. Investors in companies like N4 do not need the product to get to market to make money. Companies with products years away from market at clinical trial stage are often valued significantly higher than we are now.
The question for investors is whether N4's potential newsflow from Nuvec & Nanogenics can take it to a much higher level than we see today.